Top Growth Trends in the Psoriatic Arthritis Treatment Market: Key Insights and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the psoriatic arthritis treatment market?
The market for psoriatic arthritis treatments has been flourishing in the past few years. Its size is expected to surge from $10.93 billion in 2024 to $12 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.8%. Contributing factors to the past growth include better diagnosis processes, growing instances of psoriatic arthritis, heightened awareness about the condition and its available treatments, a broadening selection of approved interventions for psoriatic arthritis, governmental backing for research and development initiatives, and amplified investments from the pharmaceutical industry.
What will be the psoriatic arthritis treatment market size in the future?
The market size for treatment of psoriatic arthritis is predicted to undergo substantial expansion in the upcoming years, reaching $17.16 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 9.4%. The growth projected for the forecast period is associated with factors such as personalized medicine, the advent of biologics and small molecules, and an ever-increasing array of treatment options along with the worldwide aging populace. Key trends to note for the forecast period include the progression in biologics, oral small molecules, targeting of specific pathways, telemedicine and monitoring from remote locations, patient-focused care, and empirical evidence from real-world experience.
Get your psoriatic arthritis treatment market report here!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp
What main drivers are fueling expansion in the psoriatic arthritis treatment market?
The growth of the market for psoriatic arthritis treatment is spurred by an increase in the occurrence of psoriasis and psoriatic arthritis. Both psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory disorders that can greatly affect a person’s health and quality of life. Psoriasis is linked to inflammatory arthritis, also known as psoriatic arthritis (PsA), occurring in about 30% of patients with psoriasis. As an example, the National Library of Medicine, a US-based government entity, published reports in January 2024 stating that the annual incidence of psoriatic arthritis in patients with psoriasis falls between 1.9% to 2.7% per 100 patients. The probability of developing PsA rises considerably over time, with rates of 1.7% at 5 years, 3.1% at 10 years, and soaring to 20.5% at 30 years after a diagnosis of psoriasis. As such, an increase in the prevalence of psoriasis and psoriatic arthritis is driving the growth of this market.
What key areas define the segmentation of the global psoriatic arthritis treatment market?
The psoriatic arthritis treatment market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics
4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp
Who are the dominant players expanding their reach in the psoriatic arthritis treatment market?
Major companies operating in the psoriatic arthritis treatment market include AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., CB Biosciences Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Abbott Laboratories, Eisai Inc., Janssen Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, LEO Pharma A/S, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.
How are evolving market trends shaping psoriatic arthritis treatment Strategies?
Key players in the psoriatic arthritis treatment market are channeling their efforts towards the creation of innovative products such as targeted biologic therapy. The aim is to provide personalized and more impactful treatment solutions that tackle the core inflammatory processes, boost patient outcomes, and improve the quality of life for those affected by this persistent disease. Targeted biologic therapy is a treatment that harnesses strategically fashioned drugs or substances to interfere with specific molecules that spark the growth and dissemination of cancer cells. Its main goal is to lessen harm to healthy cells while optimizing therapeutic results. For instance, in January 2022, a biopharmaceutical firm located in the U.S known as AbbVie, which is involved in the discovery and development of medications, declared that the U.S. Food and Drug Administration (FDA) approved SKYRIZI (risankizumab-rzaa). SKYRIZI® (risankizumab-rzaa) is an inhibitor of interleukin-23. It is chiefly employed to treat active psoriatic arthritis by curbing inflammation at its roots through blocking the p19 subunit of IL-23. Clinical trials have exhibited significant advancements in joint symptoms and overall disease activity, with a large number of patients achieving clinical remission and an improved quality of life. This treatment option, provided via subcutaneous injection, offers convenience to patients and permits the modulation of dosing schedules to meet specific patient needs.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3458
Which regions are emerging as leaders in the psoriatic arthritis treatment market?
North America was the largest region in the psoriatic arthritis treatment market in 2024. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Browse Through More Similar Reports By The Business Research Company:
Hydroxychloroquine Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hydroxychloroquines-global-market-report
Arthritis Monoclonal Antibodies Global Market Report 2024
Musculoskeletal Disorders Drugs Global Market Report 2022
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
